Kestra Medical Technologies (NASDAQ:KMTS) Insider Traci Umberger Sells 100,000 Shares of Stock

Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) insider Traci Umberger sold 100,000 shares of the firm’s stock in a transaction on Wednesday, October 21st. The stock was sold at an average price of $27.18, for a total value of $2,718,000.00. Following the sale, the insider owned 195,825 shares in the company, valued at $5,322,523.50. This trade represents a 33.80% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Kestra Medical Technologies Trading Up 3.7%

Kestra Medical Technologies stock traded up $1.01 during trading on Thursday, hitting $28.32. The company’s stock had a trading volume of 739,134 shares, compared to its average volume of 349,841. The stock has a market capitalization of $1.69 billion, a price-to-earnings ratio of -10.61 and a beta of 0.51. The stock’s fifty day moving average is $26.40 and its 200 day moving average is $23.73. Kestra Medical Technologies, Ltd. has a 1-year low of $17.34 and a 1-year high of $30.00. The company has a debt-to-equity ratio of 0.33, a quick ratio of 4.69 and a current ratio of 4.69.

Kestra Medical Technologies (NASDAQ:KMTS) last issued its quarterly earnings results on Monday, September 14th. The company reported ($0.75) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.61) by ($0.14). The business had revenue of $30.97 million during the quarter. Kestra Medical Technologies had a negative return on equity of 63.83% and a negative net margin of 140.43%. As a group, equities research analysts predict that Kestra Medical Technologies, Ltd. will post -2.45 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Sei Investments Co. raised its stake in shares of Kestra Medical Technologies by 22.6% in the 1st quarter. Sei Investments Co. now owns 237,116 shares of the company’s stock valued at $4,726,000 after acquiring an additional 43,753 shares during the period. The Manufacturers Life Insurance Company increased its holdings in Kestra Medical Technologies by 6.6% in the 1st quarter. The Manufacturers Life Insurance Company now owns 92,515 shares of the company’s stock valued at $1,844,000 after purchasing an additional 5,731 shares in the last quarter. Corient Private Wealth LP increased its holdings in Kestra Medical Technologies by 284.2% in the 2nd quarter. Corient Private Wealth LP now owns 60,614 shares of the company’s stock valued at $1,542,000 after purchasing an additional 44,839 shares in the last quarter. Bank of New York Mellon Corp raised its position in Kestra Medical Technologies by 47.2% in the first quarter. Bank of New York Mellon Corp now owns 70,113 shares of the company’s stock valued at $1,397,000 after purchasing an additional 22,471 shares during the period. Finally, Spartan Wealth Advisory Services LLC acquired a new position in Kestra Medical Technologies during the 1st quarter worth approximately $603,000.

Analysts Set New Price Targets

KMTS has been the topic of several research analyst reports. Wolfe Research set a $30.00 target price on shares of Kestra Medical Technologies in a research report on Wednesday, July 15th. Evercore started coverage on shares of Kestra Medical Technologies in a research report on Tuesday. They set an “outperform” rating and a $34.00 price target for the company. Oppenheimer began coverage on shares of Kestra Medical Technologies in a research note on Tuesday, July 21st. They set a “market perform” rating on the stock. Royal Bank Of Canada set a $30.00 target price on Kestra Medical Technologies in a report on Tuesday, September 15th. Finally, Wall Street Zen downgraded Kestra Medical Technologies from a “hold” rating to a “sell” rating in a research report on Saturday, September 12th. Five investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $29.00.

About Kestra Medical Technologies

Kestra Medical Technologies, Inc is a medical technology company focused on developing and commercializing wearable solutions for patients at risk of sudden cardiac arrest. Its primary product is the ASSURE wearable cardioverter defibrillator, a wearable device designed to continuously monitor a patient’s heart rhythm and deliver a therapeutic shock when clinically necessary.

The company’s platform combines cardiac monitoring, arrhythmia detection and defibrillation capabilities in a wearable system intended for use outside the hospital.